Rasagiline, Parkinson neuroprotection, and delayed-start trials: Still no satisfaction?

Neurology

Volumn 74, Issue 14, 2010, Pages 1143-1148

  Ahlskog, J Eric ^a   Uitti, Ryan J ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RASAGILINE;

CLINICAL TRIAL; HUMAN; NEUROPROTECTION; PALLIATIVE THERAPY; PARKINSON DISEASE; PATIENT SATISFACTION; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 77951017105     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181d7d8e2     Document Type: Review

References (27)

1. Ahlskog JE. I can't get no satisfaction: still no neuroprotec-tion for Parkinson disease. Neurology 2007;69:1476-1477.
2. Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ. Practice Parameter: neuroprotec-tive strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:976-982. (Pubitemid 44044779)
3. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321:1364-1371.
4. Parkinson Study Group. Effects of tocopherol and depre-nyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
5. Fowler JS, Volkow ND, Logan J, et al. Slow recovery of human brain MAO B after L-deprenyl (selegiline) withdrawal. Synapse 1994;18:86-93.
6. Parkinson Study Group. Impact of deprenyl and tocoph-erol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996;39:29-36.
7. Parkinson Study Group. Impact of deprenyl and tocoph-erol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39:37-45.
8. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
9. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54:93-101.
10. Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 2003;60:381-389.
11. Albin RL, Frey KA. Initial agonist treatment of Parkinson's disease: a critique. Neurology 2003;60:390-394.
12. Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radio-tracer imaging in Parkinson disease. Neurology 2005;64: 208-215.
13. Olanow CW, Schapira AHV, LeWitt PA, et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2006;5: 1013-1020.
14. The Parkinson Study Group PRECEPT Investigators. The mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson's disease. Neurology 2007;69: 1480-1490.
15. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61:561-566.
16. Olanow CW, Hauser RA, Jankovic J, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord 2008;23:2194-2201.
17. D'Agostino RB, Sr. The delayed-start study design. N Engl J Med 2009;361:1304-1306.
18. Tatton WG, Chalmers-Redman RM. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegen-eration. Neurology 1996;47:S171-S183.
19. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59:1937-1943.
20. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62:241-248.
21. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365:947-954.
22. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361:1268-1278.
23. Goetz CG, Wuu J, McDermott MP, et al. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord 2008;23:690-699.
24. Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord 2009;24:564-573.
25. Schapira AHV, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 2006;59:559-562.
26. Cotzias GC, Miller ST, Tang LC, Papavasiliou PS, Wang YY. Levodopa, fertility and longevity. Science 1977;196: 549-551.
27. Ahlskog JE. Challenging conventional wisdom: the etio-logic role of dopamine oxidative stress in Parkinson's disease. Mov Disord 2005;20:271-282.